Aspergillosis due to Voriconazole Highly Resistant Aspergillus fumigatus and Recovery of Genetically Related Resistant Isolates From Domiciles
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Azole resistance is an emerging problem in Aspergillus fumigatus and complicates the management of patients with Aspergillus-related diseases. Selection of azole resistance may occur through exposure to azole fungicides in the environment. In the Netherlands a surveillance network was used to investigate the epidemiology of resistance selection in A. fumigatus. METHODS: Clinical A. fumigatus isolates were screened for azole resistance in 8 university hospitals using azole agar dilution plates. Patient information was collected using an online questionnaire and azole-resistant A. fumigatus isolates were analyzed using gene sequencing, susceptibility testing, and genotyping. Air sampling was performed to investigate the presence of resistant isolates in hospitals and domiciles. RESULTS: Between December 2009 and January 2011, 1315 A. fumigatus isolates from 921 patients were screened. A new cyp51A-mediated resistance mechanism (TR46/Y121F/T289A) was observed in 21 azole-resistant isolates from 15 patients in 6 hospitals. TR46/Y121F/T289A isolates were highly resistant to voriconazole (minimum inhibitory concentration ≥16 mg/L). Eight patients presented with invasive aspergillosis due to TR46/Y121F/T289A, and treatment failed in all 5 patients receiving primary therapy with voriconazole. TR46/Y121F/T289A Aspergillus fumigatus was recovered from 6 of 10 sampled environmental sites. CONCLUSIONS: We describe the emergence and geographical migration of a voriconazole highly resistant A. fumigatus that was associated with voriconazole treatment failure in patients with invasive aspergillosis. Recovery of TR46/Y121F/T289A from the environment suggests an environmental route of resistance selection. Exposure of A. fumigatus to azole fungicides may facilitate the emergence of new resistance mechanisms over time, thereby compromising the use of azoles in the management of Aspergillus-related diseases.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The highest rates of both azole and echinocandin resistance are observed in Candida glabrata and Candida tropicalis30 (Table 1).”
From Drug resistance and tolerance in fungi. (2020) · cites this paper as [30]
Citations
Cites
De Pauw, B., Walsh, T. J., Donnelly, J. P., Stevens, D. A., Edwards, J. E., Calandra, T., Pappas, P. G., Maertens, J., Lortholary, O., Kauffman, C. A., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/588660 · Cited by 4,917
Walsh, T. J., Anaissie, E. J., Denning, D. W., Herbrecht, R., Kontoyiannis, D. P., Marr, K. A., Morrison, V. A., Segal, B. H., Steinbach, W. J., Stevens, D. A., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/525258 · Cited by 2,706
Howard, S. J., Cerar, D., Anderson, M. J., Albarrag, A., Fisher, M. C., Pasqualotto, A. C., Laverdiere, M., Arendrup, M. C., Perlin, D. S., & Denning, D. W. (2009) · Emerging Infectious Diseases · doi:10.3201/eid1507.090043 · Cited by 750
Emergence of Azole Resistance in Aspergillus fumigatus and Spread of a Single Resistance Mechanism
Snelders, E., van der Lee, H. A. L., Kuijpers, J., Rijs, A. J. M. M., Varga, J., Samson, R. A., Mellado, E., Donders, A. R. T., Melchers, W. J. G., & Verweij, P. E. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050219 · Cited by 727
Self-citationAzole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use?
Verweij, P. E., Snelders, E., Kema, G. H., Mellado, E., & Melchers, W. J. (2009) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(09)70265-8 · Cited by 604
Self-citationMellado, E., Garcia-Effron, G., Alcázar-Fuoli, L., Melchers, W. J. G., Verweij, P. E., Cuenca-Estrella, M., & Rodríguez-Tudela, J. L. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01092-06 · Cited by 490
Self-citationClinical Implications of Azole Resistance in Aspergillus fumigatus, the Netherlands, 2007–2009
van der Linden, J. W. M., Snelders, E., Kampinga, G. A., Rijnders, B. J. A., Mattsson, E., Debets-Ossenkopp, Y. J., Kuijper, E. J., Van Tiel, F. H., Melchers, W. J. G., & Verweij, P. E. (2011) · Emerging Infectious Diseases · doi:10.3201/eid1710.110226 · Cited by 446
Self-citationTriazole Fungicides Can Induce Cross-Resistance to Medical Triazoles in Aspergillus fumigatus
Snelders, E., Camps, S. M. T., Karawajczyk, A., Schaftenaar, G., Kema, G. H. J., van der Lee, H. A., Klaassen, C. H., Melchers, W. J. G., & Verweij, P. E. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031801 · Cited by 427
Self-citationPossible Environmental Origin of Resistance of Aspergillus fumigatus to Medical Triazoles
Snelders, E., Huis in 't Veld, R. A. G., Rijs, A. J. M. M., Kema, G. H. J., Melchers, W. J. G., & Verweij, P. E. (2009) · Applied and Environmental Microbiology · doi:10.1128/aem.00231-09 · Cited by 423
Self-citationMultiple-Triazole–Resistant Aspergillosis
Verweij, P. E., Mellado, E., & Melchers, W. J. G. (2007) · New England Journal of Medicine · doi:10.1056/nejmc061720 · Cited by 380
Self-citation
Research works printed but not linked: 1
- Van der Linden, 2009, Azole containing agar plates as a screening tool for azole resistance of Aspergillus fumigatus, Mycoses, 52, S1
Cited by
Items 201–300 of 349
Infections in the Cancer Patient
Marchetti, O., Tissot, F., & Calandra, T. (2016) · Elsevier eBooks · doi:10.1016/b978-0-7020-6285-8.00079-4 · Cited by 22
Bernal‐Martínez, L., Gil, H., Rivero-Menéndez, O., Gago, S., Cuenca‐Estrella, M., Mellado, E., & Alastruey‐Izquierdo, A. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01083-17 · Cited by 20
“Other emerging mechanisms of resistance have also been described, such as two point mutations (Y121F and T289A) in combination with a 46-bp TR in the promoter (13), the point mutation Y121F alone (14), or a 53-bp TR with no associated point mutations (15, 16).”
Limited evidence of fungicide-driven triazole-resistant Aspergillus fumigatus in Hamilton, Canada
Ashu, E. E., Kim, G. Y., Roy-Gayos, P., Dong, K., Forsythe, A., Giglio, V., Korfanty, G. A., Yamamura, D. L. R., & Xu, J. (2017) · Canadian Journal of Microbiology · doi:10.1139/cjm-2017-0410 · Cited by 19
Fungal Infection of Cystic Fibrosis Patients—Single Center Experience
Garczewska, B., Jarzynka, S., Kuś, J., Skorupa, W., & AUGUSTYNOWICZ-KOPEĆ, E. M. (2016) · Advances in respiratory medicine · doi:10.5603/piap.2016.0017 · Cited by 19
Snelders, E., Celia-Sanchez, B. N., Nederlof, Y. C., Zhang, J., Kortenbosch, H. H., Zwaan, B. J., Tehupeiory-Kooreman, M. C., Giraldo-López, A., van Dijk, K., Wang, L., et al. (2025) · mBio · doi:10.1128/mbio.03652-24 · Cited by 19
Self-citationAzole-Resistant Aspergillus fumigatus: What You Need To Know
Lockhart, S. R., Beer, K. D., & Toda, M. (2019) · Clinical Microbiology Newsletter · doi:10.1016/j.clinmicnews.2019.12.003 · Cited by 18
Hosseini, P., Keniya, M. V., Sagatova, A. A., Toepfer, S., Müller, C., Tyndall, J. D. A., Klinger, A., Fleischer, E., & Monk, B. C. (2024) · Journal of Fungi · doi:10.3390/jof10120820 · Cited by 18
Nami, S., Baradaran, B., Mansoori, B., Kordbacheh, P., Rezaie, S., Falahati, M., Khosroshahi, L. M., Safara, M., & Zaini, F. (2017) · Advanced Pharmaceutical Bulletin · doi:10.15171/apb.2017.007 · Cited by 18
Ribeiro, H. A., Vieira, L. S., Scindia, Y. M., Adhikari, B., Wheeler, M., Knapp, A., Schroeder, W. J., Mehrad, B., & Laubenbacher, R. (2022) · Journal of The Royal Society Interface · doi:10.1098/rsif.2021.0806 · Cited by 18
Gautam, P., Mushahary, D., Hassan, W., Upadhyay, S. K., Madan, T., Sirdeshmukh, R., Sundaram, C. S., & Sarma, P. U. (2016) · Medical Mycology · doi:10.1093/mmy/myv122 · Cited by 18
Pilmis, B., Garcia‐Hermoso, D., Alanio, A., Catherinot, É., Scemla, A., Jullien, V., Bretagne, S., & Lortholary, O. (2018) · American Journal of Transplantation · doi:10.1111/ajt.14940 · Cited by 17
Wang, F., Yao, S., Cao, D., Ju, C., Yu, S., Xu, S., Fang, H., & Yu, Y. (2020) · Journal of Hazardous Materials · doi:10.1016/j.jhazmat.2020.123200 · Cited by 17
Molecular Epidemiology of Aspergillus fumigatus in Chronic Pulmonary Aspergillosis Patients
van der Torre, M. H., Shen, H., Rautemaa‐Richardson, R., Richardson, M. D., & Frazer, L. N. (2021) · Journal of Fungi · doi:10.3390/jof7020152 · Cited by 17
Global epidemiology of azole resistance in Aspergillus fumigatus
Fengler, A., Bader, O., Cornely, O. A., Kurzai, O., Meis, J. F. G. M., Morio, F., & Hamprecht, A. G. (2025) · JAC-Antimicrobial Resistance · doi:10.1093/jacamr/dlaf219 · Cited by 16
Wiederhold, N. P. (2023) · Current Fungal Infection Reports · doi:10.1007/s12281-023-00469-x · Cited by 17
Occurrence of Aspergillus fumigatus azole resistance in soils from Switzerland
Schürch, S., Gindro, K., Schnée, S., Dubuis, P., Codina, J. M., Wilhelm, M., Riat, A., Lamoth, F., & Sanglard, D. (2023) · Medical Mycology · doi:10.1093/mmy/myad110 · Cited by 16
“14 In a milestone study, Fraaije et al. 40 addressed fungicides MICs of several azole-resistant A. fumigatus isolates and revealed high MICs to the methyl benzimidazole carbamate (MBC) fungicide carbendazim, to the QoI fungicide pyraclostrobin, and to the SDHI fungicide boscalid.”
BackgroundBusca, A., Tortorano, A. M., & Pagano, L. (2015) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2015.09.002 · Cited by 15
“More recently, a new cyp51Amediated resistance mechanism (TR46/Y121F/T289A) has been detected, conferring VCZ resistance [minimum inhibitory concentration (MIC) 16 mg/L], although the activity of ITC and PCZ was also reduced in the majority of isolates [52].”
BackgroundBuckle, J. (2015) · Elsevier eBooks · doi:10.1016/b978-0-7020-5440-2.00007-3 · Cited by 15
Jeanvoine, A., Rocchi, S., Reboux, G., Grenouillet, F., Benassarou, M., Chirouze, C., & Millon, L. (2016) · Scandinavian Journal of Infectious Diseases · doi:10.1080/23744235.2016.1193791 · Cited by 15
“fumigatus strains carrying the TR34/L98H mutation or others, have been described in different countries like the Netherlands, Denmark, the United Kingdom, Belgium, Germany or France.[4,6] Here, we present a case of invasive sinusal aspergillosis due to an azole-resistant A.”
BackgroundInfluentialPugliese, M., Matić, S., Prethi, S., Gisi, U., & Gullino, M. L. (2018) · PLoS ONE · doi:10.1371/journal.pone.0200569 · Cited by 14
Loeffert, S. T., Hénaff, L., Dupont, D., Bienvenu, A., Dananché, C., Cassier, P., Bénet, T., Wallon, M., Gustin, M., & Vanhems, P. (2018) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2018.05.007 · Cited by 15
Walker, T. A., Lockhart, S. R., Beekmann, S. E., Polgreen, P. M., Santibanez, S., Mody, R. K., Beer, K. D., Chiller, T. M., & Jackson, B. R. (2018) · Emerging Infectious Diseases · doi:10.3201/eid2401.170971 · Cited by 13
Kang, Y., Li, Q., Yao, Y., Xu, C., Qiu, Z., Jia, W., Li, G., & Wang, P. (2024) · Infection and Drug Resistance · doi:10.2147/idr.s440363 · Cited by 14
Kang, Y., Ma, W., Li, Q., Wang, P., & Jia, W. (2025) · Scientific Reports · doi:10.1038/s41598-025-00187-z · Cited by 16
“Notable examples include TR34/L98H and TR46/Y121F/T289A, which confer resistance to itraconazole (ITC) and voriconazole (VRC), respectively, but typically result in a pan-azole resistance phenotype when assessed in vitro 29–31 .”
Pérez‐Pitarch, A., Guglieri-López, B., Ferriols‐Lisart, R., Pérez, A., Ezquer, C., Hernández‐Boluda, J. C., Piñana, J. L., Navarro, D., Solano, C., & Almiñana, M. A. (2019) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000657 · Cited by 13
Loeffert, S. T., Melloul, É., Dananché, C., Hénaff, L., Bénet, T., Cassier, P., Dupont, D., Guillot, J., Botterel, F., Wallon, M., et al. (2017) · BMJ Open · doi:10.1136/bmjopen-2017-018109 · Cited by 13
“fumigatus isolates in patients who have never ever been subjected to azole therapy.(51) Determination of the prevalence of azole Figure 3 Flow chart of protocol study.”
Avenues for antifungal drug discovery and development: where to now?
Vassilopoulos, S., & Mylonakis, E. E. (2022) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2022.2098950 · Cited by 14
“the development of resistance to current antifungal therapies, including the emergence of multi-drug resistant species of Candida auris [2] and the increased incidence of voriconazoleresistant Aspergillus fumigatus isolates [3], underscore the need for new approaches in the management of fungal diseases.”
BackgroundBuil, J. B., Meis, J. F., Melchers, W. J. G., & Verweij, P. E. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00256-16 · Cited by 12
“Until now, TR46/Y121F/T289A was considered to have emerged exclusively through environmental azole fungicide exposure (10).”
BackgroundSelf-citationPrigitano, A., Esposto, M. C., Grancini, A., Passera, M., Paolucci, M., Stanzani, M., Sartor, A., Candoni, A., Pitzurra, L., Innocenti, P., et al. (2020) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2020.01.016 · Cited by 13
Impact of self-reported environmental mould exposure on COPD outcomes
Kosmidis, C., Hashad, R., Mathioudakis, A. G., McCahery, T., Richardson, M. D., & Vestbo, J. (2021) · Pulmonology · doi:10.1016/j.pulmoe.2021.05.003 · Cited by 12
“In addition, the same resistant Aspergillus strains were cultured from respiratory secretions of COPD patients and from patients with invasive aspergillosis and their homes.(17,18) In a small number of COPD patients, quantity of fungi in floor dust was associated with poorer lung function.”
BackgroundAntifungal Resistance in Pulmonary Aspergillosis
Verweij, P. E., Song, Y., Buil, J. B., Zhang, J., & Melchers, W. J. G. (2024) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0043-1776997 · Cited by 13
“32,33 Resistance selection is caused by fungicides that exhibit activity against A. fumigatus and possess a molecule structure similar to that of medical azoles.”
BackgroundSelf-citationRößler, S., Bader, O., Stölzel, F., Sommer, U. J., Spieß, B., Geibel, S., Buchheidt, D., Groß, U., Baretton, G. B., Jacobs, E., et al. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00270-17 · Cited by 12
“bearing the cyp51A TR46 Y121F T289A mutation in 2009 (23), that allele has been detected in environmental and clinical strains, including two from allogeneic HSCT”
BackgroundSantoro, K., Matić, S., Gisi, U., Spadaro, D., Pugliese, M., & Gullino, M. L. (2017) · Pest Management Science · doi:10.1002/ps.4642 · Cited by 12
“…from Europe (including Italy) and India showing the presence of DMI resistant isolates (TR 34 +L98H, TR 46 +Y121F and T289A) in the environment (Snelders et al., 2009; Mortensen et al., 2010; Chowdhary et al., 2012; van der Linden et al., 2013; Prigitano et al., 2014; van Ingen et al., 2015).”
Rocchi, S., Reboux, G., & Millon, L. (2015) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2015.10.008 · Cited by 11
Field-Crop Soils in Eastern France: Coldspots of Azole-Resistant Aspergillus fumigatus
Godeau, C., Morin‐Crini, N., Crini, G., Guillemin, J., Voisin, A.-S., Dousset, S., & Rocchi, S. (2023) · Journal of Fungi · doi:10.3390/jof9060618 · Cited by 11
A Case for Antifungal Stewardship
Miller, R. A. (2018) · Current Fungal Infection Reports · doi:10.1007/s12281-018-0307-z · Cited by 12
Mahmoudi, S., Badali, H., Rezaie, S., Azarnezhad, A., Barac, A. M., Kord, M., Ahmadikia, K., Aala, F., Askari, F. A., Meis, J. F. G. M., et al. (2019) · Molecular Biology Reports · doi:10.1007/s11033-019-04909-1 · Cited by 11
Hu, M., Li, Z., Li, D., Zhao, J., Chen, Y., Wang, Z., Chen, F., & Han, L. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00291-21 · Cited by 11
Arendrup, M. C., Verweij, P. E., Mouton, J. W., Lagrou, K., & Meletiadis, J. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky218 · Cited by 11
Self-citationLysine acetylation as drug target in fungi: an underexplored potential in Aspergillus spp.
Wassano, N. S., Leite, A. B., Reichert‐Lima, F., Schreiber, A. Z., Moretti, N. S., & Damásio, A. (2020) · Brazilian Journal of Microbiology · doi:10.1007/s42770-020-00253-w · Cited by 12
Hull, C. M., Purdy, N. J., & Moody, S. C. (2014) · Future Microbiology · doi:10.2217/fmb.13.160 · Cited by 11
Pontes, L., Beraquet, C. A. G., Arai, T., Watanabe, A., Moretti, M. L., & Schreiber, A. Z. (2022) · Medical Mycology Case Reports · doi:10.1016/j.mmcr.2022.02.002 · Cited by 10
Kühbacher, A., Merschak, P., Haas, H., Liebl, M., Müller, C., & Gsaller, F. (2023) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00918-23 · Cited by 10
Computational Modeling of Macrophage Iron Sequestration during Host Defense against Aspergillus
Adhikari, B., Scindia, Y. M., Vieira, L. S., Ribeiro, H. D. A. L., Masison, J., Yang, N., Fonseca, L. L., Wheeler, M., Knapp, A., Mei, Y., et al. (2022) · mSphere · doi:10.1128/msphere.00074-22 · Cited by 10
Salehi, Z., Sharifynia, S., Jamzivar, F., Shams‐Ghahfarokhi, M., Poorabdollah, M., Abtahian, Z., Nasiri, N., Marjani, M., Moniri, A., Salehi, M., et al. (2023) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-023-04608-7 · Cited by 10
“On the other hand, there are increasing reports emerging from azole-resistant strains of Aspergillus species [6, 7].”
BackgroundImmunotherapy for opportunistic infections: Current status and future perspectives
Fuji, S., Löffler, J., Einsele, H., & Kapp, M. (2016) · Virulence · doi:10.1080/21505594.2016.1207038 · Cited by 10
Macedo, D., Leonardelli, F., Cabeza, M. S., Gamarra, S. P., & García‐Effrón, G. (2021) · Medical Mycology · doi:10.1093/mmy/myab052 · Cited by 9
Sun, Y., Gao, L., Zhang, Y., Yang, J. Y., & Zeng, T. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.579362 · Cited by 9
“Nevertheless, azole resistance, especially in A. fumigatus, has increased alarmingly and is responsible for the high mortality rate of IA (van der Linden et al., 2011; Verweij et al., 2016; Perez-Cantero et al., 2020).”
BackgroundAspergillus Species Causing Invasive Fungal Disease in Queensland, Australia
Stewart, A. G., Isler, B., Simos, P., Farquhar, D., George, N., Golmayo, M., & Heney, C. (2023) · Mycopathologia · doi:10.1007/s11046-023-00713-5 · Cited by 9
Lee, S., Xu, S., Bivila, C. P., Lee, H., Park, M. S., Lim, Y. W., & Yamamoto, N. (2015) · PLoS ONE · doi:10.1371/journal.pone.0138725 · Cited by 9
“fumigatus resistant to medical triazoles found in environments such as compost [27], soil [22, 23, 27, 28], and outdoor air [22, 24].”
BackgroundLinking calcium signaling and mitochondrial function in fungal drug resistance
Bowyer, P., Bromley, M., & Denning, D. W. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1920497117 · Cited by 10
Paluch, M., Lejeune, S., Hecquet, E., Prévötat, A., Deschildre, A., & Fréalle, É. (2019) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2019.01.001 · Cited by 9
Azole Antifungal Drugs: Mode of Action and Resistance
Garcia‐Rubio, R., Monteiro, M. C., & Mellado, E. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-809633-8.20731-0 · Cited by 9
Caldera, J. R., Dayo, A., Wiederhold, N. P., & Yang, S. (2025) · Journal of Clinical Microbiology · doi:10.1128/jcm.00291-25 · Cited by 8
Antifungal Resistance in Animal Medicine: Current State and Future Challenges
Álvarez‐Pérez, S., García, M. E., Anega, B., & Blanco, J. L. (2021) · Fungal biology · doi:10.1007/978-3-030-69507-1_10 · Cited by 10
Antifungal Stewardship in Invasive Fungal Infections, a Systematic Review
Procacci, C., Marras, L., Maurmo, L., Vivanet, G., Scalone, L., & Bertolino, G. (2024) · Advances in experimental medicine and biology · doi:10.1007/5584_2024_798 · Cited by 9
Seyedmousavi, S., & Verweij, P. E. (2017) · Springer eBooks · doi:10.1007/978-1-4939-0694-9_22 · Cited by 9
Self-citationVehreschild, J. J., Koehler, P. A., Lamoth, F., Prattes, J., Rieger, C. T., Rijnders, B. J. A., & Teschner, D. (2020) · Medical Mycology · doi:10.1093/mmy/myaa079 · Cited by 8
Self-citationSerrano‐Lobo, J., Gómez, A., Muñóz, P., Escribano, P., & Guinea, J. (2021) · Medical Mycology · doi:10.1093/mmy/myab072 · Cited by 8
Cascio, G. L., Bazaj, A., Trovato, L., Sanna, S., Andreoni, S., Blasi, E., Conte, M., Fazii, P., Oliva, E., Lepera, V., et al. (2022) · Infection and Drug Resistance · doi:10.2147/idr.s367082 · Cited by 8
Álvarez‐Pérez, S., García, M. E., Martínez‐Nevado, E., & Blanco, J. L. (2023) · Research in Veterinary Science · doi:10.1016/j.rvsc.2023.104993 · Cited by 8
Invasive Fungal Infections in the Child with Chronic Granulomatous Disease
Warris, A., & Henriet, S. (2014) · Current Fungal Infection Reports · doi:10.1007/s12281-013-0168-4 · Cited by 9
van der Torre, M. H., Whitby, C., Eades, C. P., Moore, C. B., Frazer, L. N., Richardson, M. D., & Rautemaa‐Richardson, R. (2020) · Journal of Fungi · doi:10.3390/jof6040208 · Cited by 8
“Additionally, some of these studies show a worrying trend of ARAf collected from the patients’ own homes, suggesting a wider degree of environmental dissemination [29,30].”
Resultvan de Peppel, R. J., van der Beek, M. T., Visser, L. G., de Boer, M. G. J., & Wallinga, J. (2018) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2018.10.021 · Cited by 8
Exposure to Fungi in Health Care Facilities
Sabino, R. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-809633-8.21034-0 · Cited by 9
Paul, S. K., Stamnes, M. A., & Moye-Rowley, S. (2023) · G3 Genes Genomes Genetics · doi:10.1093/g3journal/jkad173 · Cited by 8
Azole Resistance in Aspergillus fumigatus Isolates
Vaezi, A., Haghani, I., Davoudi, M. M., Mousavi, B., Ansari, S., Noshak, M. A., Khodavaisy, S., & Badali, H. (2013) · Majallah-i dānishgāh-i ̒ulūm-i pizishkī-i Māzandarān/Journal of Mazandaran University of Medical Sciences · Cited by 7
D’Agostino, M., Tesse, N., Lavergne, R., Pape, P. L., Frippiat, J., Machouart, M., & Debourgogne, A. (2021) · Journal of Medical Microbiology · doi:10.1099/jmm.0.001399 · Cited by 7
Antifungal therapy for the treatment of CNS infections
Aboabdo, M., & Mishkin, A. D. (2024) · Current Fungal Infection Reports · doi:10.1007/s12281-024-00492-6 · Cited by 7
“Local resistance factors and epidemiology should be considered when selecting an antifungal with some areas reporting higher levels of azole resistance, attributed to agricultural fungicide use [45].”
Mechanisms of Resistance to Antifungal Agents
Perlin, D. S. (2015) · ASM Press eBooks · doi:10.1128/9781555817381.ch130 · Cited by 9
Microcalorimetry Assay for Rapid Detection of Voriconazole Resistance in Aspergillus fumigatus
Tafin, U. F., Meis, J. F. G. M., & Trampuž, A. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01379-13 · Cited by 7
Land use drives drug resistance in an airborne human fungal pathogen
Kortenbosch, H. H., Briggeman, B., Marquez, F. R., Auxier, B., de Bruin, S., Zwaan, B. J., & Snelders, E. (2025) · The ISME Journal · doi:10.1093/ismejo/wraf246 · Cited by 6
From patterns to prediction: machine learning and antifungal resistance biomarker discovery
Thorn, V., & Xu, J. (2025) · Canadian Journal of Microbiology · doi:10.1139/cjm-2024-0248 · Cited by 7
Wang, S., Yang, S., Ma, J., Zhang, C., Li, Z., Wang, M., Yu, W., & Liu, G. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1387278 · Cited by 6
Bralet, T., Risco‐Castillo, V., Valsecchi, I., Laidebeure, S., Sailler, A., Lécu, A., Botterel, F., Guillot, J., Arné, P., & Jouvion, G. (2023) · Veterinary Research Communications · doi:10.1007/s11259-023-10220-z · Cited by 6
“This method had already been used in previous studies (Van der Linden et al. 2013; Choukri et al. 2015; Monpierre et al. 2021).”
Proteomic Differences between Azole-Susceptible and -Resistant Aspergillus fumigatus Strains
Vermeulen, E., Carpentier, S., Kniemeyer, O., Sillen, M., Maertens, J. A., & Lagrou, K. (2018) · Advances in Microbiology · doi:10.4236/aim.2018.81007 · Cited by 8
Yazgan, Z., Çalışkan, R., & Aygün, G. (2025) · Journal of Fungi · doi:10.3390/jof11090659 · Cited by 5
“In Belgium and the Netherlands, the TR46/Y121F/T289A mutation was first detected in panazole-resistant strains in 2014 [50,51].”
Birštonas, L., Hortschansky, P., Bauer, I., Alcanzo, E. M., Kühbacher, A., Mertens, B., Müller, C., Brakhage, A. A., & Gsaller, F. (2025) · mBio · doi:10.1128/mbio.01854-25 · Cited by 5
“In fact, most prevalent mechanisms of resistance, termed TR34/L98H and TR46/Y121F/T289A, involve overexpression of cyp51A (22, 23).”
Moosig, F., Reinhold‐Keller, E., Holl‐Ulrich, K., Feller, A. C., Bley, T. A., Holle, J. U., Zwerina, J., Lamprecht, P., Dalhoff, K., Venhoff, N., et al. (2012) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-012-0988-6 · Cited by 7
The State-of-the-Art Mycology Laboratory: Visions of the Future
Arendrup, M. C., Posteraro, B., Sanguinetti, M., & Guinea, J. (2014) · Current Fungal Infection Reports · doi:10.1007/s12281-014-0212-z · Cited by 7
“fumigatus isolates have been found in the environment and in patients in Europe, Asia, and Africa [39, 41–43, 50, 130–132].”
BackgroundAzole Resistance in Moulds—Approach to Detection in a Clinical Laboratory
Chowdhary, A., Masih, A., & Sharma, C. (2016) · Current Fungal Infection Reports · doi:10.1007/s12281-016-0265-2 · Cited by 5
Molecular Detection of Resistance to Azole Components
Posteraro, B., Vella, A., Carolis, E. D., & Sanguinetti, M. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-6515-1_24 · Cited by 5
Spadaro, D., Matić, S., Prencipe, S., Ferrero, F., Borreani, G., Gisi, U., & Gullino, M. L. (2019) · Pest Management Science · doi:10.1002/ps.5566 · Cited by 5
A Low‐Cost Tebuconazole‐Based Screening Test for Azole‐Resistant Aspergillus fumigatus
Brackin, A. P., Shelton, J., Abdolrasouli, A., Fisher, M. C., & Sewell, T. R. (2020) · Current Protocols in Microbiology · doi:10.1002/cpmc.112 · Cited by 5
“Currently, the majority of azole resistance monitoring studies are constrained to European countries, motivated primarily by the clinical emergence of ARAf in these regions (Snelders, van der Lee, et al., 2008; Van Der Linden et al., 2013; Verweij et al., 2009).”
BackgroundAn expanded agar‐based screening method for azole‐resistant Aspergillus fumigatus
Lucio, J. L., González-Jiménez, I., Garcia‐Rubio, R., Cuétara, M. S., & Mellado, E. (2021) · Mycoses · doi:10.1111/myc.13400 · Cited by 5
IFISTRATEGY: Spanish National Survey of Invasive Fungal Infection in Hemato-Oncologic Patients
Vallejo, C. T., Jarque, I., Fortün, J., Casado, A., & Pemán, J. (2023) · Journal of Fungi · doi:10.3390/jof9060628 · Cited by 5
“Isolates harboring TR46/Y121F/T289A were not only recovered from epidemiologically unrelated patients, most of whom were azole naive, but were also recovered from environmental samples, suggesting an environmental route of resistance selection [15].”
InfluentialSoto-Debrán, J. C., Sánchez, F. J., Calvo-López, A. B., Alguacil-Cuéllar, L., Hrynzovska, A., Mellado, E., dos Santos, S. G., Alcázar‐Fuoli, L., & Alastruey‐Izquierdo, A. (2026) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1722314 · Cited by 4
“…2022; Sewell et al., 2019; Shelton et al., 2022; Tsitsopoulou et al., 2018; Resendiz-Sharpe et al., 2021; Wang et al., 2018; Viegas et al., 2022; Van Der Linden et al., 2013; Sabino et al., 2021; Paluch et al., 2019; Toyotome et al., 2017; Onishi et al., 2017; Gonzalez-Jimenez et al., 2021;…”
Recent Epidemiological Changes in Infectious Diseases
Pucci, M. J., Callebaut, C., Cathcart, A. L., & Bush, K. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12405-9 · Cited by 7
Andrade, E. F., Poester, V. R., Esperon, B. M., Trápaga, M. R., Hidalgo, J. E. D., Ferreira, F., de Souza, M., Severo, C. B., von Groll, A., & Xavier, M. O. (2025) · Brazilian Journal of Microbiology · doi:10.1007/s42770-024-01604-7 · Cited by 5
Jain, N., Jansone, I., Obidenova, T., Sīmanis, R., Meisters, J., Straupmane, D., & Reinis, A. (2021) · Life · doi:10.3390/life11101002 · Cited by 6
“, the use of azole-based fungicides for cereal and grape cultivation in European member countries) have led to the increased incidence of resistant fungal strains in the environment [1,10].”
BackgroundPugliese, M., Matić, S., Prethi, S., Gisi, U., & Gullino, M. L. (2018) · PLoS ONE · doi:10.1371/journal.pone.0202835 · Cited by 4
Pontes, L., Giordano, A. L. P. L., Reichert‐Lima, F., Beraquet, C. A. G., Pigolli, G. L., Arai, T., Ribeiro, J. D., Gonçalves, A. C., Watanabe, A., Goldman, G. H., et al. (2024) · Journal of Fungi · doi:10.3390/jof10070461 · Cited by 3
Pulmonary aspergillosis: diagnosis and treatment
Quereshi, S., Paralikar, P., Pandit, R., Razzaghi‐Abyaneh, M., Kon, K. V., & Rai, M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-804543-5.00012-9 · Cited by 4
Résistance aux azolés chez Aspergillus
Guegan, H., & Gangneux, J. (2017) · Journal des Anti-infectieux · doi:10.1016/j.antinf.2017.10.001 · Cited by 5
Arbabi, A., Haghani, I., Naghshvar, F., Charati, J. Y., Abastabar, M., Hedayati, M. T., Davoodi, L., Shokohi, T., Amiri, F. T., Yahyazadeh, Z., et al. (2025) · Europe PMC (PubMed Central) · doi:10.22034/cmm.2025.345248.1686 · Cited by 2
“…data documenting increasing azole resistance rates, largely attributed to mutations in the cyp51A gene (specific amino acid changes in the Cyp51A protein, combined with tandem repeats [TR] in the gene promoter, such as TR 34/L98H and TR 46/Y121F/T289) and environmental fungicide exposure [42, 43].”
Aspergillosis-Attributable Mortality in the United States: Analysis of Death Certificate Data
Walsh, T. J., Sicignano, D. J., Mastropietro, M., Lovelace, B., & Coleman, C. I. (2025) · Clinical Infectious Diseases · doi:10.1093/cid/ciaf653 · Cited by 2
Davies, A. A., Spruijtenburg, B., Meijer, E. F. J., Osaigbovo, I. I., Balogun, O. J., Adekoya, A. O., Gbaja-Biamila, T. A., Meis, J. F. G. M., & Oladele, R. O. (2025) · African Journal of Laboratory Medicine · doi:10.4102/ajlm.v14i1.2674 · Cited by 2
“15,34,35,36 Outside Africa, the prevalence of azole-resistant clinical isolates in Europe steadily increased from 1.7 % in 1997 to 9 % in 2009, 37 and 15 % as of 2018, 38 while it was 4.3 % in a single centre study from China, 39 and 3.5 % in the United States.”
InfluentialBiologie et diagnostic des infections à Aspergillus
Gangneux, J., Bouchara, J. P., & Chabasse, D. (2013) · Cited by 3
Emergence of a Pathogenic Fungus Resistant to Triazole Antifungal Drugs
Rocchi, S., Godeau, C., Crini, G., & Snelders, E. (2021) · Environmental chemistry for a sustainable world · doi:10.1007/978-3-030-69079-3_3 · Cited by 4
Arıkan-Akdağlı, S., & Rex, J. H. (2017) · Springer eBooks · doi:10.1007/978-3-319-47266-9_34 · Cited by 2
Metadata
- Authors
- van der Linden, J. W. M., Camps, S. M. T., Kampinga, G. A., Arends, J. P. A., Debets-Ossenkopp, Y. J., Haas, P. J. A., Rijnders, B. J. A., Kuijper, E. J., van Tiel, F. H., Varga, J., Karawajczyk, A., Zoll, J., Melchers, W. J. G., & Verweij, P. E.
- Affiliations
- Radboud University Nijmegen (NL)
- University Medical Center Groningen (NL)
- Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
- University Medical Center Utrecht (NL)
- Erasmus MC (NL)
- Leiden University Medical Center (NL)
- University of Szeged (HU)
- Radboud University Medical Center (NL)
- ORCID
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-05-10
- Volume
- 57
- Issue
- 4
- Pages
- 513-520
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2142912010
- Cited by
- 342
- References
- 31
- Citations by year
- 2026: 5 · 2025: 17 · 2024: 15 · 2023: 21 · 2022: 13 · 2021: 28 · 2020: 25 · 2019: 21 · 2018: 32 · 2017: 38 · 2016: 38 · 2015: 40 · 2014: 34 · 2013: 13
- FWCI
- 30.27
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Leiden Repository (Leiden University) (submittedVersion)
- Research Publications (Maastricht University) (submittedVersion, other-oa)
- Radboud Repository (Radboud University) (submittedVersion)
- Funders
- Pfizer
- Gilead Sciences
- ZonMw
- Astellas Pharma
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
- Keywords
- Aspergillus fumigatus, voriconazole resistance, azole resistance, invasive aspergillosis, cyp51A mutations, azole fungicides, environmental isolates, treatment failure, antifungal resistance surveillance
- MeSH terms
- Aged, Air Microbiology, Antifungal Agents, Aspergillosis, Aspergillus fumigatus, Child, Female, Genes, Fungal, Genotype, Hospitals, Humans, Male, Middle Aged, Netherlands, Pyrimidines, Surveys and Questionnaires, Residence Characteristics, Selection, Genetic, Triazoles, Mycological Typing Techniques, Treatment Failure, Sequence Analysis, DNA, Drug Resistance, Fungal, Young Adult, Molecular Typing, Voriconazole
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.